iCo Therapeutics is a biotechnology company focused on redosing or reformulating drugs with clinical history for new or expanded indications. The company has exclusive worldwide rights to three products: iCo-007, in phase 2 for the treatment of Diabetic Macular Edema (DME); iCo-008 (Bertilimumab), a product with phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. For more information visit the company’s Web site at www.icotherapeutics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: